• ENO1, Macrophage Metabolism, and Cardiac Repair

  2026-11-10

  A preclinical study evaluates whether ENO1 links macrophage metabolism to postinfarction inflammation and tissue repair, and whether an acid-responsive siRNA nanocarrier can test that mechanism. The reported findings connect ENO1 silencing with altered glycolysis, lactate-associated signaling, inflammatory macrophage behavior, and cardiac remodeling readouts, while remaining bounded by the cellular and murine models used.

• SIRT1, Type H Vessels, and Bone Aging

  2026-11-10

  A preclinical study links age-associated SIRT1 decline with coordinated deterioration of type H vasculature and osteogenic activity. Pharmacological and genetic perturbations support a model in which endothelial–osteogenic communication is mediated in part through soluble factors and β-catenin signaling, while remaining limited by the study’s sex, model, and mechanical-assessment boundaries.

• SIRT1, Type H Vessels, and Bone Aging

  2026-11-09

  A preclinical study links age-associated SIRT1 decline with coordinated impairment of type H vasculature, endothelial function, and osteogenic activity. Its findings support a β-catenin-associated model of endothelial–osteogenic communication while leaving important questions about sex, biomechanics, vascular specificity, and in vivo causality unresolved.

• ENO1, Macrophage Metabolism, and Cardiac Repair

  2026-11-09

  A preclinical study examines ENO1 as a metabolic regulator of inflammatory macrophages after myocardial infarction and evaluates an acid-responsive nanocarrier for targeted siRNA delivery. The reported findings connect ENO1 silencing with altered glycolysis, lactate–KLF4 signaling, reduced inflammatory macrophage features, and improved structural and functional cardiac measures in mice, while leaving important questions about mechanism, model transferability, and longer-term safety.

• hPSC Regionalization and Differentiation Competence

  2026-11-08

  A comparative study links variable differentiation competence among human pluripotent stem-cell lines to anterior–posterior epiblast identity and locus-specific bivalent chromatin states. Its chromatin-restoration experiments support a reversible model, while line dependence, limited molecular replication and genomic changes constrain generalization.

• Epiblast Regionalization and hPSC Competence

  2026-11-07

  A study of human pluripotent stem-cell lines links anterior–posterior identity to locus-specific bivalent chromatin and shows that chromatin restoration can recover differentiation competence in selected models.

• SIRT1, Type H Vessels, and Skeletal Aging

  2026-11-06

  A preclinical study examined whether age-related SIRT1 decline links vascular and osteogenic dysfunction in bone. Its findings support a model in which SIRT1-associated β-catenin signaling and soluble endothelial–osteogenic communication influence skeletal aging, while leaving important model-specific uncertainties.

• ENO1, Macrophage Metabolism, and Cardiac Repair

  2026-11-06

  A preclinical study examines ENO1 as a metabolic regulator of inflammatory macrophages after myocardial infarction and evaluates an acid-responsive nanocarrier for targeted siRNA delivery. The findings connect ENO1 silencing with altered glycolysis, lactate signaling, macrophage state, and improved cardiac remodeling in mice, while leaving important mechanistic and translational questions unresolved.

• When Experimental Context Changes a Cancer Result

  2026-11-05

  The same growth, viability, or tumor-suppression readout can support very different conclusions depending on the perturbation, model, comparator, and molecular measurement behind it. The HNRNPU–lactylation study illustrates why genetic, pharmacological, proteasome-control, and in vivo contexts must be interpreted separately.

• EX 527 and the SIRT1–Bone Vascular Axis

  2026-11-05

  Liu et al. used EX 527 (SEN0014196) as a pharmacological loss-of-function comparator to test whether SIRT1 links type H vessels, endothelial activity, and osteogenesis in aged bone. The findings support a SIRT1–β-catenin mechanism across cellular and murine models, while leaving questions about pharmacological specificity, model scope, and human translation.

• Epiblast Regionalization and hPSC Competence

  2026-11-04

  A comparative study links variable differentiation competence among human pluripotent stem-cell lines to anterior–posterior epiblast identity and locus-specific bivalent chromatin states. The findings support chromatin restoration as a mechanistic rescue strategy while highlighting line-specific responses, limited assay replication and genomic-stability concerns.

• What (R)-MG132 Can Establish in Proteasome Controls

  2026-11-04

  The cervical cancer study supports a lactate–HNRNPU–PHGDH axis, while (R)-MG132 has a narrower interpretive role as a documented stereochemical control for proteasome-dependent mechanisms. The two evidence streams should be kept distinct: one addresses tumor biology, and the other helps frame how proteostasis-related assay effects might be interpreted.

• What (R)-MG132 Can—and Cannot—Show

  2026-11-03

  The cervical-cancer study supports a lactate–HNRNPU K181–PHGDH pathway that links post-translational regulation to serine metabolism. That mechanism should not be conflated with evidence for proteasome dependence: (R)-MG132 is best interpreted as an MG-132 enantiomer used for proteasome inhibition validation, while the reported tumor phenotypes were investigated primarily through genetic perturbation and pazopanib.

• What Narasin’s Ionophore Action Can Explain

  2026-11-03

  Narasin (sodium salt) is described as an ionophore antibiotic whose membrane-level effects are associated with distinct signaling, cell-death, and coccidiosis readouts. The key interpretive point is that these observations occur at different biological levels and should not be treated as one universally established pathway.

• When Context Changes an EX 527 Result

  2026-11-02

  A SIRT1-inhibition result can mean biochemical target engagement, pathway perturbation, or evidence about tissue remodeling depending on the model, comparator, and readout. An age-related bone study shows why EX 527 is best interpreted as a pharmacological loss-of-function comparator rather than as a treatment for skeletal disease.

7166 records 1/478 page Next 12345 下5页 Last page